XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Related Party Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2021
Mar. 17, 2021
Mar. 31, 2020
Dec. 31, 2020
Sep. 30, 2020
Apr. 28, 2020
Nov. 26, 2019
Dec. 31, 2018
Apr. 16, 2018
Mar. 31, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total   $ (2,531,000)   $ (4,743,000)              
Assets, Current, Total $ 16,904,000 16,904,000     $ 15,298,000            
Liabilities, Current, Total $ 10,491,000 10,491,000     $ 6,143,000            
Interest Paid, Excluding Capitalized Interest, Operating Activities   2,142,000   1,950,000              
Amortization of Debt Discount (Premium)   $ 908,000   522,000              
Boyalife Asset Holding II [Member] | Convertible Debt [Member]                      
Debt Instrument, Interest Rate, Stated Percentage 22.00% 22.00%     22.00%            
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 1.80 $ 1.80     $ 1.80       $ 1.80 $ 16.10  
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]                      
Line of Credit Facility, Maximum Borrowing Capacity                     $ 10,000,000
Long-term Line of Credit, Total             $ 10,000,000        
Debt Instrument, Interest Rate, Stated Percentage         22.00%            
Interest Paid, Excluding Capitalized Interest, Operating Activities     $ 2,082,000                
Amortization of Debt Discount (Premium)   $ 827,000   546,000              
Interest Payable $ 550,000 550,000   $ 443,000              
Interest Expense, Debt, Excluding Amortization   $ 550,000     $ 2,082,000            
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) 12,000,000                    
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) 500,000                    
ImmuneCyte [Member]                      
Equity Method Investment, Ownership Percentage 8.64% 8.64%       18.79%   20.00%      
Dilution Gain from Equity Method Investments   $ 262,000                  
Equity Method Investment Accumulated Gain Loss   (428,000)                  
Income (Loss) from Equity Method Investments, Total   0     $ 13,000            
Equity Method Investment, Aggregate Cost $ 0 0                  
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total   (253,000)                  
Assets, Current, Total 3,514,000 3,514,000                  
Liabilities, Current, Total $ 2,375,000 $ 2,375,000                  
ImmuneCyte [Member] | HealthBanks Biotech [Member]                      
Equity Method Investment, Ownership Percentage           75.16%   80.00%      
ImmuneCyte [Member] | Private Institution [Member]                      
Equity Method Investment, Ownership Percentage           6.05%